Douglas Jermasek
CIK: 0001955273
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Unicycive Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (3 total)
- May 14, 2026UNCY
Unicycive Therapeutics, Inc.
Award(A)DirectRestricted Stock Units
169.5K shares- - May 14, 2026UNCY
Unicycive Therapeutics, Inc.
Award(A)DirectRestricted Stock Units
169.5K shares- - Jul 28, 2025UNCY
Unicycive Therapeutics, Inc.
Award(A)DirectStock Options
10K shares-
1-3 of 3 transactions
About Jermasek Douglas
Jermasek Douglas (SEC CIK 0001955273) files insider reports with the SEC as EVP, Corporate Strategy of Unicycive Therapeutics, Inc. (UNCY).
Signal8 holds 3 ownership filings by Jermasek Douglas, all Form 4s, filed between Jul 30, 2025 and Jun 15, 2026. Those filings report 3 transactions, from Jul 28, 2025 to May 14, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Jermasek Douglas's filings is in MOUNTAIN VIEW, CA.
Recent filings by Jermasek Douglas
Other insiders filing for Unicycive Therapeutics, Inc. (UNCY)
- Manning Meredith, Director
- Kenkare-Mitra Sara, Director
- Laumas Sandeep, Director
- Gupta Shalabh K., CEO
- Gupta Pramod, EVP, Pharmaceuticals and BD
- Townsend John, CFO